Astellas Pharma (OTCMKTS:ALPMY) Stock Price Crosses Below 50 Day Moving Average – Should You Sell?

Posted by on Jul 11th, 2026

Astellas Pharma Inc. (OTCMKTS:ALPMY – Get Free Report) shares crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $13.76 and traded as low as $13.1850. Astellas Pharma shares last traded at $13.25, with a volume of 134,199 shares trading hands.

Analyst Ratings Changes

A number of research firms recently weighed in on ALPMY. Jefferies Financial Group raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 24th. Zacks Research raised Astellas Pharma from a “hold” rating to a “strong-buy” rating in a report on Tuesday, June 23rd. Two research analysts have rated the stock with a Strong Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Astellas Pharma presently has an average rating of “Moderate Buy”.

Get Our Latest Analysis on Astellas Pharma

Astellas Pharma Stock Performance

The company’s fifty day simple moving average is $13.76 and its two-hundred day simple moving average is $14.64. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.84 and a current ratio of 1.09. The stock has a market capitalization of $23.98 billion, a P/E ratio of 12.34 and a beta of 0.07.

Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) last issued its quarterly earnings data on Monday, April 27th. The company reported $0.33 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.19 by $0.14. Astellas Pharma had a return on equity of 24.19% and a net margin of 13.66%.The company had revenue of $3.38 billion during the quarter, compared to analysts’ expectations of $3.28 billion. As a group, equities analysts forecast that Astellas Pharma Inc. will post 1.25 EPS for the current year.

Astellas Pharma Company Profile

(Get Free Report)

Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.

Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).

Read More

Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.